Thrombosis & Thromboembolism 2022 (CME VIDEOS)

Novel Targets For Atherosclerosis Prevention

• What’s New with TG and AngPTL3 – Aruna D. Pradhan, MD, MPH, MSc
• What’s New with Lp(a) – Samia Mora, MD
• What’s New with LDL and ApoB – Jorge Plutzky, MD
• What’s New with Inflammatory Targets – Paul M. Ridker, MD, MPH
• Discussion/Q&A – John F. Keaney, Jr., MD – Moderator

Peripheral Arterial Disease

• PAD – Pathways for Optimizing Cardiovascular and Limb Outcomes – Marc P. Bonaca, MD, MPH
• Discussion/Q&A – Marie D. Gerhard-Herman, MD – Moderator

Heart Failure

• Heart Failure and Venous Thromboembolism – Samuel Z. Goldhaber, MD
• More Than Just Diabetes and Heart Failure – SGLT2 – Deepak L. Bhatt, MD, MPH
• More Than Just Diabetes and Heart Failure – GLP1 – Brendan M. Everett, MD, MPH
• Heart Failure – Reduced Ejection Fraction – Marc A. Pfeffer, MD, PhD
• Discussion/Q&A – Akshay Suvas Desai, MD, MPH – Moderator
• Heart Failure – Preserved Ejection Fraction – Scott D. Solomon, PhD
• Heart Failure – Middle-of-the-Road Ejection Fraction – Navigating the Alphabet Soup – Michele A. Hamilton, MD
• CMR Imaging of Imaging of Heart Failure – Raymond Y. Kwong, MD, MPH

Atrial Fibrillation & Coronary Disease

• Dual Antiplatelet Therapy and Anticoagulation – Michelle L. O’Donoghue, MD, MPH
• How to Manage the Anticoagulation Around Ablation and Cardioversions and Watchmans for AF – Bruce A. Koplan, MD

Anticoagulation

• Dose-Reduced Direct Oral Anticoagulants – Efficacy and Safety – Behnood Bikdeli, MD, MS
• Duration of Anticoagulation – Arterial Thrombosis – Navigating Limitations in Data and Variations in Practice – Teresa Carman, MD, RPVI, MSVM
• Duration of Anticoagulation – Venous Thrombosis – Gregory Piazza, MD, MS
• Novel Anticoagulation Targets – Factor XI and XII Inhibitors – Jeffrey I. Weitz, MD
• Discussion/Q&A – Samuel Z. Goldhaber, MD – Moderator

Racial Disparities In Arterial And Venous Thrombosis

• Racial Disparities in Healthcare – Cassandra M. Pierre, MD, MSc
• Racial Disparities in Arterial and Venous Thrombosis – Karlyn A. Martin, MD
• Discussion/Q&A – Gregory Piazza, MD, MS – Moderator

Genetics

• VTE Prediction – Using Genetics as a Powerful Tool – Nicholas A. Marston, MD, MPH
• Clonal Hematopoiesis of Indeterminate Potential (CHIP) – Association with VTE & PAD – Peter Libby, MD
• Discussion/Q&A – Gregory Piazza, MD, MS – Moderator

Covid And Thrombosis

• COVID and Thrombosis – Mechanisms and Epidemiology – Gregory Piazza, MD, MS
• Prevention of VTE in COVID-19 Patients – Behnood Bikdeli, MD, MS
• Discussion/Q&A – Samuel Z. Goldhaber, MD – Moderator

VTE Prevention

• VTE Prophylaxis for Orthopedic Surgery – Samuel Z. Goldhaber, MD
• Discussion/Q&A – Ebrahim Barkoudah, MD, MPH – Moderator

PE Reperfusion

• Device Therapy for PE Reperfusion – Navigating a Rapidly Changing Landscape – Gregory Piazza, MD, MS
• Systemic Fibrinolysis (PEITHO-3) – Samuel Z. Goldhaber, MD
• Adventures with Hypertrophic Cardiomyopathy – 1958-2022 – Eugene Braunwald, MD

Pulmonary Hypertension and Thrombosis

• Chronic Thromboembolic Pulmonary Hypertension – Bradley A. Maron, MD
• Pulmonary Hypertension After PE That is Not Chronic Thromboembolic Pulmonary Hypertension – Jane A. Leopold, MD, FACC, FAHA, FSCAIc

Post-Thrombotic Syndrome

• Post-thrombotic Syndrome – Epidemiology and Medical Therapy – Susan R. Kahn, MD, MSc, FRCPC, ABIM
• Intervention, Acute Intervention, and Chronic Venous Obstructive Disease – Suresh Vedantham, MD
• Discussion/Q&A – Arvind K. Pandey, MD – Moderator

VTE and Cancer

• Vascular Cardio-Oncology – Javid Moslehi, MD
• Prevention of Thrombotic Complications of Cancer and Cancer Therapy – Simon Mantha, MD, MPH
• Treatment of Cancer-Associated Thrombosis – Michael B. Streiff, MD
• Discussion/Q&A – Jean Connors, MD – Moderator